Trial
NCT02338232
Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation
UnknownTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Hackensack Meridian Health
Collaborators
—
Condition
GVHD
Intervention
Telmisartan
Why stopped
Lack of Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-04-02